Drug intelligence / Profile preview

pegapamodutide

Development stage: Phase 2
Lead developer: OPKO Health
Modality: Peptides, Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

Pegapamodutide is a synthetic peptide and analog of oxyntomodulin, developed as an investigational therapy for obesity and type 2 diabetes mellitus. It acts as a dual agonist at the glucagon receptor and the glucagon-like peptide 1 (GLP-1) receptor, mimicking the effects of endogenous incretin hormones to regulate glucose metabolism and reduce body weight. The drug is PEGylated to enhance its pharmacokinetic properties. Pegapamodutide has been developed by Eli Lilly, OPKO Health, Transition Therapeutics, and LeaderMed Group. As of October 2024, it has completed phase II clinical trials for both obesity and type 2 diabetes mellitus[3][4][5][7].

Other names: Pegapamodutide [USAN]Oxyntomodulin analog

Targets

GLP1R (GLP-1R)GCGR (Glucagon receptor)

Beyond the preview

Go deeper on pegapamodutide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pegapamodutide.

Explore the full profile